Matinas BioPharma Holdings, Inc. (MTNB) | Investment Case

1. Company Snapshot

1.a. Company Description

Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates.It develops products using its lipid nanocrystal (LNC) platform technology.The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides.

Its lead product candidate is LYPDISO, a prescription-only omega-3 free fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions.The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients.In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections.

Matinas BioPharma Holdings, Inc.has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc.for the development of oral formulations.

The company was incorporated in 2013 and is based in Bedminster, New Jersey.

Show Full description

1.b. Last Insights on MTNB

Matinas BioPharma Holdings, Inc.'s recent performance was driven by strategic initiatives and leadership enhancements. The company secured $3.3 million in gross proceeds through the sale of Series C Convertible Preferred Stock and accompanying warrants, bolstering its financial position. Additionally, the appointment of seasoned biotech leaders, including Keith Murphy and Edward Neugeboren, to the Board of Directors brings valuable expertise and oversight. Furthermore, Evelyn D'An's appointment as Audit Committee Chair and independent director provides an experienced voice in governance and risk management.

1.c. Company Highlights

Last Price	0.85
Change Percentage	7.58%
Open	0.83
Previous Close	0.79
Market Cap ( Millions)	5
Volume	7222
Year High	3.09
Year Low	0.47
M A 50	1.38
M A 200	1.08

FCF Yield	-205.41%
Dividend Yield	0.00%
ROE	-249.82%
Debt / Equity	36.13%
Net Debt / EBIDTA	35.51%
Price To Book	0.66
Price Earnings Ratio	-0.25
Price To FCF	-0.49
Price To sales	4.56
EV / EBITDA	-0.15

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

Mar -11

Source: globenewswire.com

Matinas BioPharma Announces Agreement for the Acquisition of Preferred Stock and Appointment of Dr. Robin L. Smith to the Board of Directors

Feb -13

Source: globenewswire.com

Matinas BioPharma Appoints Evelyn D'An to Board of Directors as Audit Committee Chair

Feb -07

Source: globenewswire.com

Matinas BioPharma Receives NYSE Noncompliance Notice

Jan -10

Source: globenewswire.com

Matinas BioPharma Announces the Termination of MAT2203 Partnership Negotiations and Implements Immediate Workforce Reduction

Oct -31

Source: globenewswire.com

Matinas BioPharma Holdings, Inc. (MTNB) Q2 2024 Earnings Call Transcript

Aug -15

Source: seekingalpha.com

Matinas BioPharma Reports Second Quarter 2024 Financial Results and Provides a Business Update

Aug -14

Source: globenewswire.com

Matinas BioPharma to Webcast Conference Call to Discuss Second Quarter 2024 Financial Results and Provide a Business Update on August 14, 2024

Aug -07

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (8.50%)

6. Segments

Novel Pharmaceutical Products

Expected Growth: 8.5%

Matinas BioPharma's novel pharmaceutical products drive 8.5% growth, fueled by increasing demand for innovative treatments, strategic partnerships, and expanding pipeline of lipid nanocrystal (LNC) platform-based products, which offer improved bioavailability and targeted delivery. Strong R&D investments and regulatory approvals also contribute to the company's rapid expansion.

7. Detailed Products

Lipid Nano-Crystal (LNC) Platform

A proprietary drug delivery technology that enables the nano-encapsulation of small molecules, peptides, and nucleic acids

MAT9001

A prescription-only, omega-3 free fatty acid formulation for the treatment of severe hypertriglyceridemia

MAT2203

An oral, encochleated formulation of amphotericin B for the treatment of invasive fungal infections

MAT2507

A novel, oral, encochleated formulation of a broad-spectrum antibiotic for the treatment of bacterial infections

8. Matinas BioPharma Holdings, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Matinas BioPharma Holdings, Inc. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the ongoing research and development in the biopharmaceutical industry.

Bargaining Power Of Customers

Matinas BioPharma Holdings, Inc. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are specialized, making it difficult for customers to switch to alternative suppliers.

Bargaining Power Of Suppliers

Matinas BioPharma Holdings, Inc. relies on a few key suppliers for raw materials and services, which gives them some bargaining power. However, the company's strong relationships with its suppliers and its ability to negotiate contracts mitigate this risk.

Threat Of New Entrants

The biopharmaceutical industry has high barriers to entry, including significant capital requirements, complex regulatory requirements, and the need for specialized expertise. This makes it difficult for new entrants to compete with established companies like Matinas BioPharma Holdings, Inc.

Intensity Of Rivalry

The biopharmaceutical industry is highly competitive, with many established companies competing for market share. Matinas BioPharma Holdings, Inc. faces intense competition from companies with similar products and pipelines, which can lead to pricing pressure and reduced market share.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	15.60%
Debt Cost	3.95%
Equity Weight	84.40%
Equity Cost	12.07%
WACC	10.80%
Leverage	18.48%

11. Quality Control: Matinas BioPharma Holdings, Inc. passed 4 out of 9 key points

Strong Liquidity

Low Debt

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Revance Therapeutics

A-Score: 4.2/10

Value: 9.0

Growth: 6.1

Quality: 6.2

Yield: 0.0

Momentum: 1.0

Volatility: 2.7

1-Year Total Return ->

TRACON Pharmaceuticals

A-Score: 3.7/10

Value: 9.6

Growth: 6.9

Quality: 5.2

Yield: 0.0

Momentum: 0.5

Volatility: 0.3

1-Year Total Return ->

Unicycive Therapeutics

A-Score: 3.6/10

Value: 6.4

Growth: 4.6

Quality: 3.6

Yield: 0.0

Momentum: 6.5

Volatility: 0.7

1-Year Total Return ->

Vericel

A-Score: 3.4/10

Value: 1.0

Growth: 7.9

Quality: 6.1

Yield: 0.0

Momentum: 2.0

Volatility: 3.7

1-Year Total Return ->

Matinas BioPharma

A-Score: 2.8/10

Value: 7.8

Growth: 4.2

Quality: 3.2

Yield: 0.0

Momentum: 1.0

Volatility: 0.3

1-Year Total Return ->

Inovio Pharmaceuticals

A-Score: 1.9/10

Value: 6.4

Growth: 0.3

Quality: 3.2

Yield: 0.0

Momentum: 0.5

Volatility: 1.0

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

14.99%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

10.80%

Matinas BioPharma Holdings, Inc. - US5768101058

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on MTNB

1.c. Company Highlights

Better Quality

Medium Volatility

Fairly Valued

More Volatile

Weak Momentum

Cheaper

Earnings Miss

Earnings Beats

Lower Quality

2. Transcript Summary

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (8.50%)

6. Segments

Novel Pharmaceutical Products

Expected Growth: 8.5%

7. Detailed Products

Lipid Nano-Crystal (LNC) Platform

MAT9001

MAT2203

MAT2507

8. Matinas BioPharma Holdings, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: Matinas BioPharma Holdings, Inc. passed 4 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

0.85$

Current Price

0.85$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA